Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Microbiota-Host-Irinotecan Axis: A New Insight Toward Irinotecan Chemotherapy
Bei Yue, Ruiyang Gao, Zhengtao Wang, et al.
Frontiers in Cellular and Infection Microbiology (2021) Vol. 11
Open Access | Times Cited: 49

Showing 1-25 of 49 citing articles:

Role of the gut microbiota in anticancer therapy: from molecular mechanisms to clinical applications
Lin-Yong Zhao, Jia-Xin Mei, Gang Yu, et al.
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 159
A Review of Gut Microbiota‐Derived Metabolites in Tumor Progression and Cancer Therapy
Qiqing Yang, Bin Wang, Qinghui Zheng, et al.
Advanced Science (2023) Vol. 10, Iss. 15
Open Access | Times Cited: 100
Roles of microbiota in pancreatic cancer development and treatment
Mariana Santos Cruz, Joseph Tintelnot, Nicola Gagliani
Gut Microbes (2024) Vol. 16, Iss. 1
Open Access | Times Cited: 21
Emerging role of gut microbiota in autoimmune diseases
Xinyi Wang, Wei Yuan, Chunjuan Yang, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 21
The gut microbiota in breast cancer development and treatment: The good, the bad, and the useful!
Deeptashree Nandi, Sheetal Parida, Dipali Sharma
Gut Microbes (2023) Vol. 15, Iss. 1
Open Access | Times Cited: 38
Exploring the potential impact of probiotic use on drug metabolism and efficacy
Carmen Purdel, Anca Ungurianu, Ines Adam-Dima, et al.
Biomedicine & Pharmacotherapy (2023) Vol. 161, pp. 114468-114468
Open Access | Times Cited: 32
The effective combination therapies with irinotecan for colorectal cancer
Yun Chai, Jingli Liu, Shuo Zhang, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access | Times Cited: 13
Bifidobacterium longum SX-1326 ameliorates gastrointestinal toxicity after irinotecan chemotherapy via modulating the P53 signaling pathway and brain-gut axis
Fenfang Yue, Xiangdi Zeng, Yufan Wang, et al.
BMC Microbiology (2024) Vol. 24, Iss. 1
Open Access | Times Cited: 12
An Organ‐on‐Chip Platform for Simulating Drug Metabolism Along the Gut–Liver Axis
Mara Lucchetti, Kehinde Aina, Léa Grandmougin, et al.
Advanced Healthcare Materials (2024) Vol. 13, Iss. 20
Open Access | Times Cited: 10
Role of the microbiome in oral cancer occurrence, progression and therapy
Zhengrui Li, Yuan Liu, Ling Zhang
Microbial Pathogenesis (2022) Vol. 169, pp. 105638-105638
Closed Access | Times Cited: 35
Microbial endocrinology: the mechanisms by which the microbiota influences host sex steroids
Sophie Cotton, Charlotte A. Clayton, Carolina Tropini
Trends in Microbiology (2023) Vol. 31, Iss. 11, pp. 1131-1142
Closed Access | Times Cited: 21
Chemotherapy-induced gastrointestinal toxicity: Pathogenesis and current management
Yunjing He, Jingrui Zheng, Binbin Ye, et al.
Biochemical Pharmacology (2023) Vol. 216, pp. 115787-115787
Closed Access | Times Cited: 19
Gastrointestinal Microbiota in Gastric Cancer: Potential Mechanisms and Clinical Applications—A Literature Review
Mengjiao Wu, Chenjun Tian, Zhenwei Zou, et al.
Cancers (2024) Vol. 16, Iss. 20, pp. 3547-3547
Open Access | Times Cited: 5
Gut Microbiome Integration in Drug Discovery and Development of Small Molecules
Patrick Jimonet, Céline Druart, Stéphanie Blanquet‐Diot, et al.
Drug Metabolism and Disposition (2024) Vol. 52, Iss. 4, pp. 274-287
Open Access | Times Cited: 4
β-Glucuronidase-triggered reaction for fluorometric and colorimetric dual-mode assay based on the in situ formation of silicon nanoparticles
Yue Li, Weiping Liu, Xinxin Jiang, et al.
Analytica Chimica Acta (2024) Vol. 1301, pp. 342471-342471
Closed Access | Times Cited: 4
Advancements in the impact of human microbiota and probiotics on leukemia
Yi Zhang, Xiaotong Zhao, Jingxian Zhang, et al.
Frontiers in Microbiology (2024) Vol. 15
Open Access | Times Cited: 4
Updated perspectives on the contribution of the microbiome to the pathogenesis of mucositis using the MASCC/ISOO framework
Andrea M. Stringer, Benjamin M. Hargreaves, Rui Amaral Mendes, et al.
Supportive Care in Cancer (2024) Vol. 32, Iss. 8
Open Access | Times Cited: 4
Managing Irinotecan-Induced Diarrhea: A Comprehensive Review of Therapeutic Interventions in Cancer Treatment
Xiaoqin Yang, Jiamei Chen, Yitao Wang, et al.
Pharmaceuticals (2025) Vol. 18, Iss. 3, pp. 359-359
Open Access
Role of gut microbiota in predicting chemotherapy-induced neutropenia duration in leukemia patients
Ying‐Zu Huang, Lihong Liao, Yanjun Jiang, et al.
Frontiers in Microbiology (2025) Vol. 16
Open Access
β‐Glucuronidase‐Expressing Lactobacillus reuteri Triggers Irinotecan Enterotoxicity Through Depleting the Regenerative Epithelial Stem/Progenitor Pool
Bei Yue, Ruiyang Gao, Ling Zhao, et al.
Advanced Science (2025)
Open Access
A pilot study of gut mucosal and faecal microbiota in rectal cancer: associations with histological response and adverse events following preoperative chemoradiotherapy
Shigenobu Emoto, Ryo Inoüe, Shin Murai, et al.
Colorectal Disease (2025) Vol. 27, Iss. 5
Open Access
The Role of Short-Chain Fatty Acids, Particularly Butyrate, in Oncological Immunotherapy with Checkpoint Inhibitors: The Effectiveness of Complementary Treatment with Clostridium butyricum 588
Massimiliano Cazzaniga, Marco Cardinali, Francesco Di Pierro, et al.
Microorganisms (2024) Vol. 12, Iss. 6, pp. 1235-1235
Open Access | Times Cited: 3
From microbes to medicine: harnessing the power of the microbiome in esophageal cancer
Xiaoyan Liu, Bang Li, Liping Liang, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 3
Randomized double-blind, placebo-controlled multicenter phase III study of prevention of irinotecan-induced diarrhea by a probiotic mixture containing Bifidobacterium BB-12®Lactobacillus rhamnosus LGG® in colorectal cancer patients
Michal Mego, Radoslav Danis, Jozef Chovanec, et al.
Frontiers in Oncology (2023) Vol. 13
Open Access | Times Cited: 8
Decreased Tissue Omega-6/Omega-3 Fatty Acid Ratio Prevents Chemotherapy-Induced Gastrointestinal Toxicity Associated with Alterations of Gut Microbiome
Kanakaraju Kaliannan, Shane O. Donnell, Kiera Murphy, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 10, pp. 5332-5332
Open Access | Times Cited: 13
Page 1 - Next Page

Scroll to top